Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis: a network meta-analysis of phase 3-4 randomized trials - PubMed
4 hours ago
- #Atopic dermatitis
- #network meta-analysis
- #JAK inhibitor
- Upadacitinib 30 mg ranked highest for achieving key efficacy endpoints (EASI-75, EASI-90, IGA 0/1, NRS response) in moderate-to-severe atopic dermatitis.
- The analysis included 33 trials with 16,334 participants from 27 reports up to July 2025.
- No significant differences found between dupilumab 300 mg and stapokibart 300 mg, or between ivarmacitinib 8 mg and upadacitinib 15 mg.
- Findings are based on indirect comparisons; head-to-head trials are needed for confirmation.